

mRNA Vaccines & Therapies

Preclinical or Clinical Bioanalysis

Every project is unique. Backed by 30 years of regulatory bioanalytical expertise and our GCP/GLP bioanalytical laboratories, we work alongside you to deliver efficient, high-quality solutions that meet your timelines and maximise value for your mRNA program.

LCMS or NMR Bioanalysis

- Pharmacokinetic (PK)/Toxicokinetic (TK) (LCMS/ICP-MS/GC-MS) – Drug Product, Lipid/LNP.
- Biodistribution (PK/TK LCMS) – Lipid/LNP
- NMR Quantification (PK/TK) – PEGylated Drug Product



Cell & Molecular

- Potency (Biological Activity, Cell based and IVT) – Drug Product, Drug Substance (mRNA)
- Biodistribution (PK/TK, QPCR/ddPCR) – Drug Substance (mRNA)
- Target Gene Activation/Expression (Fold-change Expression QPCR, ddPCR, NGS) – Target Genes (multiplexed)
- Cytotoxicity/Cell Viability (MTT/WST-1/ATP/CellTiter Glo) – Drug Product, Drug Substance (mRNA), Lipid/LNP



Immunoassay

- Pharmacokinetic (PK)/Toxicokinetic (TK) (ELISA/MSD/Gyros) – Drug Product
- Immunogenicity (ADA/Nab/Vaccines) (ELISA/MSD) – PEG, ADA to Drug Product
- Pharmacodynamic (PD)/Biomarkers (ELISA/MSD) – Cytokines, other (multiplexed)



With Intertek as your partner, you gain access to the scientific and regulatory expertise of our bioanalytical specialists, enabling you to leverage our insight to advance your drug development programs.



Our 30,000-square-foot European Centre of Excellence, located in Manchester, UK, is supported by continued investment in the latest bioanalytical technologies—positioning our services to deliver fast, cost-effective, and high-quality bioanalytical support.

Bioanalytical Services

- Method development, transfer, validation and ongoing analysis
- Expertise with a wide range of product types and sample matrices
- High-throughput preclinical and clinical studies underpinned by scientific and regulatory expertise
- LC-MS solutions for small molecules, peptides and proteins
- Cell-based bioassay development, validation and analysis
- Quantitative ligand binding assay capabilities
 - Development, validation and optimisation of quantitative ELISAs for proprietary compounds
 - Transfer and validation of existing methods
- Immunogenicity studies using a tiered approach
- Neutralization cell-based assay development, validation and sample analysis
- Biomarker solutions
- Mode of action studies
- PEGylated species bioanalysis by NMR
- Elemental analysis by ICP-MS
- Multiplexing capabilities
- Multiple platform technologies



Discover more

bioanalysis@intertek.com